Literature DB >> 33549735

Hepatic steatosis and respiratory diseases: a new panorama.

Alan Eduardo Botello-Manilla1, Guillermo Nahúm López-Sánchez1, Norberto Carlos Chávez-Tapia2, Misael Uribe3, Natalia Nuño-Lámbarri4.   

Abstract

Non-alcoholic fatty liver disease is defined as hepatic fat accumulation in more than 5% of hepatocytes, without other liver steatosis causes. It comprises a broad spectrum that can range from benign steatosis and progress to non-alcoholic steatohepatitis, fibrosis, and ultimately hepatocellular carcinoma. Non-alcoholic fatty liver is considered a multisystemic disease since it is related to multiple disorders, such as type 2 diabetes mellitus, polycystic ovary syndrome, chronic kidney disease, psoriasis, osteoporosis, hypothyroidism, cardiovascular diseases, and obstructive sleep apnea syndrome; it is becoming increasingly clear that it is also a risk factor for developing certain respiratory diseases. This article aims to understand the liver and chronic obstructive pulmonary disease mechanisms, obstructive sleep apnea syndrome, asthma, and lung cancer. Given that non-alcoholic fatty liver disease has a considerable impact on the patient's well-being and life quality, as well as on the costs they generate for the country's health services, it is essential to continue research, especially in areas such as the respiratory tract, as there is much misinformation about it.
Copyright © 2021 AEDV. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Asthma; Chronic obstructive pulmonary disease; Inflammation; Obstructive sleep apnea; Pulmonary cancer

Mesh:

Year:  2021        PMID: 33549735     DOI: 10.1016/j.aohep.2021.100320

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  3 in total

1.  Novel Thienopyrimidines as Acetyl-CoA Carboxylase Inhibitors for Treating Liver Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-04-27       Impact factor: 4.345

Review 2.  Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications.

Authors:  Doris Ogresta; Anna Mrzljak; Maja Cigrovski Berkovic; Ines Bilic-Curcic; Sanja Stojsavljevic-Shapeski; Lucija Virovic-Jukic
Journal:  J Clin Transl Hepatol       Date:  2022-01-12

3.  Greater Muscular Strength Is Associated with a Lower Risk of Pulmonary Dysfunction in Individuals with Non-Alcoholic Fatty Liver Disease.

Authors:  Jinkyung Cho; Bruce D Johnson; Kymberly D Watt; Chul-Ho Kim
Journal:  J Clin Med       Date:  2022-07-17       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.